Background: Novel therapeutic agents are more effective than DMARDs in the management of psoriatic arthritis. However, direct comparisons of efficacy between these novel therapeutic agents are lacking. Objectives: This network meta-analysis aims to compare the relative efficacies between different novel therapeutic agents. Methods: Literature searching was conducted in MEDLINE, EMBASE, Scopus, ISI Web of Science, Cochrane Library, Clinicaltrials.gov and recent rheumatology conference abstracts up to Nov 2016. 2 independent researchers analysed the articles. For inclusion, randomised, placebo-controlled trials must report the proportion of patients achieving ACR20, ACR50, ACR70 and PASI75 responses. The outcomes of this network meta-analysis were the proportion of patients achieving ACR20, ACR50, ACR70 and PASI75 responses with reference to placebo and etanercept. Results were analysed using random effect model by R statistics (version 3.3.1) with statistical package netmeta (version 0.9-2). 

